What SEC filings does IDEAYA Biosciences, Inc. submit to the SEC?

IDEAYA Biosciences, Inc. (IDYA) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about IDYA?

A Form 4 for IDYA discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from IDEAYA Biosciences, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for IDYA?

The 10-K is IDEAYA Biosciences, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all IDYA SEC filings directly on EDGAR?

You can view all historical IDEAYA Biosciences, Inc. filings on the SEC EDGAR company page for IDYA. Each filing card on this page links directly to the original SEC document.

How often does IDEAYA Biosciences, Inc. file with the SEC?

IDEAYA Biosciences, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling IDYA shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

IDYA SEC Filing News — IDEAYA Biosciences, Inc.

Latest SEC filings for IDEAYA Biosciences, Inc. (IDYA) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-08.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also o…

Sector: Healthcare Industry: Biotechnology Market Cap: $3.3B CIK: 1676725

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for IDYA currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

IDYA Filing Activity Snapshot 2026-04-13 — 2026-10-08

Insider Transactions (Form 4)

0 buys vs 2 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$8.80M

YUJIRO HATA · 2026-10-06

230,316 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for IDEAYA Biosciences, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 compensation award and 2 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×2: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-10-08

IDYA insider Hata Yujiro S (Director, President and CEO) sold 26,338 shares (~$985.4K)

Hata Yujiro S, listed as Director, President and CEO at IDEAYA Biosciences, Inc., reported an open-market sale of 26,338 IDYA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	26,338	$4.31	$113.5K
`S`	Open-market sale	25,538	$37.39	$954.8K
`S`	Open-market sale	800	$38.26	$30.6K
`M`	Option exercise derivative · Stock Option (right to buy)	26,338	—	—

Filing: Form 4 (Insider Transaction) Insider: Hata Yujiro S (Director, President and CEO) Shares: 26,338 Est. Value: $985.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

IDYA insider Ruiz Briseno Andres (Chief Accounting Officer) sold 9,550 shares (~$382.1K)

Ruiz Briseno Andres, listed as Chief Accounting Officer at IDEAYA Biosciences, Inc., reported an open-market sale of 9,550 IDYA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	9,550	$12.86	$122.8K
`S`	Open-market sale	9,550	$40.01	$382.1K
`M`	Option exercise derivative · Stock Option (Right to Buy)	9,550	—	—

Filing: Form 4 (Insider Transaction) Insider: Ruiz Briseno Andres (Chief Accounting Officer) Shares: 9,550 Est. Value: $382.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

YARNO WENDY L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: YARNO WENDY L (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

Stein Jeffrey (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Stein Jeffrey (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

ROSEN TERRY J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: ROSEN TERRY J (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

Morrison Scott W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Morrison Scott W (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

MACKEY CATHERINE J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: MACKEY CATHERINE J (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-18

IDYA insider Form 4 filed for equity award, exercise, or tax withholding

Hampton Malcolm Garret (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	20,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Hampton Malcolm Garret (Director)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. IDEAYA Biosciences, Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-10-06

IDYA Form 144 filed for proposed insider sale by YUJIRO HATA (230,316 shares) ~$8.80M

YUJIRO HATA filed a Form 144 with the SEC indicating intent to sell IDYA (IDEAYA Biosciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: YUJIRO HATA Shares: 230,316 Est. Value: $8.80M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-07

IDYA Form 144 filed for proposed insider sale by Andres Ruiz Briseno (9,550 shares) ~$382.1K

Andres Ruiz Briseno filed a Form 144 with the SEC indicating intent to sell IDYA (IDEAYA Biosciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Andres Ruiz Briseno Shares: 9,550 Est. Value: $382.1K

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for IDEAYA Biosciences, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-04

IDYA filed 8-K — material company event

IDEAYA Biosciences, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.